Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy

URN:NBN:SI:doc-59E0MDOU2021But-Hadžić, JasnaĆirić, EvaJelerčič, StašaStanič, KarmenVodušek, Ana LinaVrankar, Martinadocuments/doc/5/URN_NBN_SI_doc-59E0MDOU_001.pdfdocuments/doc/5/URN_NBN_SI_doc-59E0MDOU_001.txt55articleiss. 4str. 462-4901318-209989454083URN:NBN:SI:doc-59E0MDOUengAssociation of Radiology and OncologyRadiology and oncology (Ljubljana)BYacute toxicitychemoradiotherapydurvalumabnon-small cell lung cancerstage IIIClinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapysingle institute experience